So, for these trials, do you have any concerns? Or

Quote:

---

So, for these trials, do you have any concerns? Or, are we on a clear path?

---

From what data we do have from the CD12 trial the change in protocols seems to be good.

Quote:

---

Is there some type of test (e.g. CCR5 expression) that we could run in advance?

---

It's possible CCR5 expression tests are called for in the full protocol. That would just be a fast and dirty way of finding out who is CCR5 delta 32 without the lengthy time it would take to do genomic sequencing. There may be other genetic anomalies that would cause a leronlimab fail but I would expect them to be fairly rare. In most cases of a leronlimab fail I would expect it to be caused by incipient organ failure.